Microbot Medical Inc.

Microbot Medical reported about $13 million in cash. For the 6-month period, research and development expenses were approximately $561,000 versus $263,000 a year earlier, general and administrative expenses were approximately $1.9 million versus $140,000, and financial expenses were approximately $2.3 million versus $37,000. Management said the higher financial expenses were accounting-related, not cash items. Forward-looking guidance on the call was for a burn rate of approximately $1 million per year, cash runway of at least 24 to 30 months, and continued progress toward a late-2018 FDA submission for the Self-Cleaning Shunt.

Harel Gadot framed the quarter as evidence that the company is executing against the goals set when it went public less than 9 months earlier. He emphasized the breadth of the platform strategy, arguing that Microbot’s core capabilities and IP position it to address multiple unmet needs across shunts, endoscopy, and other lumens. His tone was confident and promotional, but he repeatedly tied that optimism to specific next steps: finishing studies, presenting initial data in Japan, and using the balance sheet to pursue partnerships or acquisitions.

David Ben Naim focused on the balance sheet and expense structure. He said Microbot had about $13 million in the bank and that, based on current planning, the company is covered for at least 24 to 30 months. He also broke out 6-month expenses: R&D of approximately $561,000, G&A of approximately $1.9 million, and financial expenses of approximately $2.3 million, noting the financial expense line was driven by revaluation/extinguishment of convertible notes and warrant liability and was not a cash outflow. In Q&A, he said the expected burn rate is approximately $1 million per year and that the company no longer has convertible notes outstanding.

Analysts pressed on burn rate, whether the company would need another financing, and whether the Self-Cleaning Shunt design was locked down. Management said the recent June raise was intended to fund 24 to 30 months and that any further financing would depend on future opportunities, though they are also pursuing nondilutive Israeli government grants. On development timing, management said the design is still being worked on, but they believe it is close to final; they reiterated that the FDA submission remains targeted for late 2018. Questions also focused on the Japan hydrocephalus conference, where management said two studies are running and Professor McAllister is expected to present initial animal data.